13F Holdings
中文EN

TRIB TRINITY BIOTECH PLC IFRS

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 888721 · Fiscal year ends 12/31

Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY12.8%
TTM net income YoY77.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.9%
Net income 3-yr CAGR—

Margins

Gross margin47.6%
Operating margin0.1%
Net margin-6.3%
FCF margin20.2%
EBITDA margin0.1%

Returns

ROE-512.3%
ROA-4.9%
ROIC (approx.)0.1%
Asset turnover0.78x

Leverage & solvency

Liabilities / assets101.7%
Debt / equity—
Current ratio3.08x
Interest coverage0.01x

Cash quality & payout

Operating cash flow / net income-3.72x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue$61.55M$56.83M$62.52M$81.15M$101.98M
Cost of revenue$40.11M$37.38M$45.25M$47.70M$53.40M
Gross profit$21.44M$19.45M$17.27M$33.45M$48.58M
R&D expense$4.54M$4.38M$4.14M$4.50M$5.08M
SG&A expense$28.82M$31.15M$26.98M$22.50M$26.39M
Operating income-$21.16M-$27.05M-$19.35M$3.94M$82,000
Interest expense$9.56M$11.05M$24.73M$7.08M$6.75M
Pretax income-$30.73M-$36.93M-$43.78M-$1.92M-$6.63M
Income tax$486,000-$59,000-$194,000-$74,000-$620,000
Net income-$31.79M-$24.02M-$41.01M$875,000-$6.39M
EBITDA-$20.96M-$27.05M-$19.35M$41.94M$122,000
EPS (diluted)—————
Weighted avg. shares (diluted)——79.54M36.99M37.75M
Balance sheet
Cash & equivalents$5.17M$3.69M$6.58M$25.91M$27.33M
Receivables$16.07M$13.90M$2.69B$2.99M$3.92M
Inventory$19.37M$19.93M$22.50M$29.12M$30.22M
Current assets$41.12M$39.04M$46.67M$72.69M$83.30M
PP&E, netmay include right-of-use assets (IFRS)$4.62M$1.89M$5.68M$5.92M$8.55M
Total assets$103.29M$59.44M$92.10M$118.89M$130.40M
Current liabilities$32.09M$15.04M$17.34M$100.49M$27.06M
Short-term debt—$210,000—$83.31M—
Long-term debt$210,000$210,000$210,000$83.31M$82.66M
Total debt$210,000$420,000$210,000$166.62M$82.66M
Total liabilities$138.47M$83.38M$94.28M$119.21M$132.62M
Shareholders' equity-$35.18M-$23.95M-$2.18M-$319,000-$2.22M
Net debt-$4.96M-$3.27M-$6.37M$140.71M$55.34M
Cash flow statement
Operating cash flow-$4.19M-$11.56M-$921,000$13.24M$23.75M
Capital expenditure$405,000$803,000$1.10M$1.81M$3.18M
Free cash flow-$4.60M-$12.36M-$2.02M$11.43M$20.58M
Investing cash flow-$22.97M$24.76M-$5.98M-$8.69M-$10.20M
Financing cash flow$28.81M-$16.04M-$12.32M-$6.02M-$2.72M
Depreciation & amortization$204,000$0$0$38.00M$40,000
Stock-based compensation$1.32M$2.07M$1.75M$1.10M$792,000

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.